Treatment of chronic hepatitis C in special groups (Q33809581)

29 July 2017

1 reference

title

Treatment of chronic hepatitis C in special groups (English)

1 reference

29 July 2017

1 reference

1 reference

Pol S

1

1 reference

29 July 2017

Zylberberg H

series ordinal

2

1 reference

29 July 2017

Fontaine H

series ordinal

3

1 reference

29 July 2017

Bréchot C

series ordinal

4

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

31 Suppl 1

1 reference

29 July 2017

page(s)

205-209

1 reference

Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Interferon treatment for chronic hepatitis C virus infection in uremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

Ribavirin antagonizes the effect of azidothymidine on HIV replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980403-6

7 January 2021

10.1016/S0168-8278(99)80403-6

Identifiers

DOI

1 reference

29 July 2017

1 reference